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Controversy exists about whether antihypertensive agents are associated with breast cancer in women, particularly whether long-term use of calcium channel blockers (CCBs) is associated with increased risk and whether long-term use of angiotensin-converting enzyme inhibitors (ACEis) is associated with decreased risk (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Most previous studies of antihypertensive agents and breast cancer have had key limitations, including the facts that duration of CCB or ACEi use was not assessed, few women with many years of use were studied, use was determined from self-reports, and/ or concomitant use of antihypertensive medications was not considered (1-9, 11).
There are important implications if alterations in breast cancer risk with long-term CCB or ACEi use are confirmed (12) . In the United States, breast cancer is the most commonly occurring cancer in women and the second-leading cause of cancer death (13) . Additionally, ACEis and CCBs both rank among the top classes of medications prescribed in the United States (14) .
The primary objective of this study was to assess risk of incident invasive breast cancer in a large cohort of women with varying durations of CCB or ACEi use. Specifically, we separately evaluated associations across discrete durations of CCB or ACEi use of 1-12 years and then, as a secondary objective, we compared risks between groups. To evaluate these associations, we employed comprehensive electronic health record, administrative, medication dispensing, and tumor data from older women with hypertension enrolled in a large integrated health-care delivery system.
METHODS

Setting and population
This retrospective cohort study was conducted at Kaiser Permanente (KP), a US health-care provider. KP includes 7 sites that together comprise the largest private, not-for-profit, integrated health-care delivery system in the United States. The 3 sites participating in this study, KP Colorado, KP Northwest (Oregon and Washington), and KP Southern California, had a combined membership exceeding 4.5 million in 2013 (KP, unpublished data). Members receive outpatient health care at KP-owned facilities; medical facilities additionally provide laboratory, radiology, and pharmacy services. All KP facilities have fully integrated ambulatory electronic health records in all patient care areas, with access from any KP location.
The overall population included women aged ≥55 years with KP membership between January 1, 1997 (KP Southern California), January 1, 1998 (KP Northwest), or January 1, 1999 (KP Colorado) and April 30, 2012 (all sites). We studied women aged 55 years or older because both breast cancer and hypertension occur more often in older women. Further, 55 years is a commonly used age cutpoint for defining menopause (15) . From the overall population, we identified the source population as persons with at least 2 coded hypertension diagnoses (International Classification of Diseases, Ninth Revision, Clinical Modification, codes 401.*-405.*) on separate dates during outpatient visits between study start and end dates. From this source population, women with a pharmacy benefit and dispensing of a CCB or ACEi were then identified.
Women with any CCB or ACEi dispensing were stratified into new users and prevalent users (Figure 1 ). New users were defined as having no dispensing of either a CCB or an ACEi during a 1-year look-back period prior to the first dispensing in the study date range. Women with any CCB or ACEi dispensing within <1 year after they met study inclusion criteria were defined as prevalent users and were not included in the study.
For new users, the date of the first CCB or ACEi dispensing was the index date. We followed these women from the index date to the date of breast cancer diagnosis or a censoring event, including a switch from a CCB to an ACEi, a switch from an ACEi to a CCB, death, disenrollment from KP, prophylactic mastectomy, or April 30, 2013, whichever occurred first.
We excluded women with any breast cancer diagnosis before the index date. Breast cancers diagnosed within 12 months after the index date were considered preexisting cancers. We incorporated a 1-year lag period after the first CCB or ACEi dispensing; women who developed breast cancer or were otherwise censored during this first year did not contribute to analyses.
The study protocol was approved by the KP Colorado Institutional Review Board; KP Southern California and KP Northwest ceded oversight to KP Colorado. The requirement for informed consent was waived.
Data sources
The data source for inclusion criteria, exposures, and most covariates was the KP Virtual Data Warehouse. The Virtual Data Warehouse contains administrative, electronic health record, and other data that have been extracted, loaded, and maintained in identically formatted tables using standardized variable names and values (16, 17) . The data source for breast cancer outcomes was the Cancer Research Network's Virtual Tumor Registry (18 (20) (21) (22) (23) . Virtual Tumor Registry and Virtual Data Warehouse data were linked through a common, unique study identifier.
Exposures and outcome
The first exposure of interest was at least 1 year of use (i.e., ≥365 days' supply dispensed) of any CCB-containing product (i.e., amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, diltiazem, or verapamil). The second exposure of interest was at least 1 year of use of any ACEi-containing product (i.e., benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, or trandolapril). Duration of use was calculated from total number of dispensings, dispensing dates, and each days' supply dispensed. Women accumulated person-time in the CCB or ACEi group until they discontinued the medication class, switched from an ACEi to a CCB or from a CCB to an ACEi, or had another censoring event.
Outcomes included incident invasive lobular or ductal carcinoma (International Classification of Diseases for Oncology codes C500-C506 and C508-C509) diagnosed after the index date and by April 30, 2013.
Covariates
Covariates initially included age (13) , body mass index (weight (kg)/height (m) 2 ) (24-26), education (2000 US Census data), year of cohort entry, alcohol abuse (International Classification of Diseases, Ninth Revision, code 291.xx or 303.xx; yes/no), tobacco use (never, former, or current smoking), history of hysterectomy, history of cardiovascular disease other than hypertension, diabetes, use of other selected medications (statins, insulin, metformin, estrogen replacement with/without progestin, and nonsteroidal antiinflammatory agents), number of ambulatory visits, receipt of mammograms (a proxy for screening bias), KP site, and race/ethnicity. We considered use of β-blockers, angiotensin receptor blockers, and diuretics because these antihypertensive agents are often used concomitantly with CCBs or ACEis, and concerns have been raised about whether they are associated with increased breast cancer risk (1, 4, 5, 9, 27, 28) .
Statistical methods
We characterized the cohort sociodemographically and checked data quality and consistency and correlations. Two covariates, history of other cardiovascular disease and tobacco use, were removed because they correlated with other variables (r > 0.40). Covariates selected a priori for inclusion were age, race/ethnicity, mammography, KP site, year of cohort entry, hysterectomy, alcohol abuse, body mass index, and use of angiotensin receptor blockers, β-blockers, diuretics, and/or statins. All other covariates were tested for significance (P < 0.10) in univariate outcome models, and the following were included in the final models: education, diabetes, and estrogen replacement therapy.
We used discrete-time survival analyses to examine associations between cumulative durations of CCB and ACEi use and breast cancer. In this method, each woman's duration of use was broken into discrete yearly periods-that is, 1-<2 years, 2-<3 years, etc., through 11-<12 years of cumulative CCB or ACEi exposure. In this expanded person-period data set, each woman had 1 record for each discrete yearly period in which she was observed and an event indicator for whether breast cancer occurred during that period. Crude breast cancer hazards for individual periods were obtained using the life-table approach. We then applied the complementary log-log binary model, regressing incident breast cancer on the yearly periods to estimate duration associations after adjusting for covariates. We selected discrete-time survival analysis with a complementary log-log link function because it is appropriate for events that can happen at any time but are only observed in discrete intervals, such as breast cancer, and the parameter estimates provide the relative hazard interpretation (hazard ratios and 95% confidence intervals) (29, 30) . Each adjusted model included time-varying covariates (age, body mass index, hysterectomy, diabetes, alcohol abuse, estrogen replacement, mammography, and use of angiotensin receptor blockers, β-blockers, diuretics, and/or statins) and fixed covariates (KP site, race/ethnicity, education, and year of cohort entry). Time-varying covariates were updated at the beginning of each period. Subsequent to assessing the hazard ratio for breast cancer for each yearly period for CCB and ACEi separately, we fitted discrete-time models treating period as a continuous variable to obtain estimated slope coefficients for examination of the linear trend in duration association. We additionally examined whether the linear slopes for duration associations were similar for CCB and ACEi and tested for significance by means of an interaction between yearly duration and drug exposure.
In the primary analyses, duration of CCB or ACEi use was computed using the cumulative numbers of days' supply of CCB or ACEi dispensed, counting the days' supply of overlapping dispensings as stockpiled medication. For example, if a woman had 20 dispensings containing 60 days' supply each, her cumulative days' supply was 1,200, regardless of whether she obtained those dispensings at 60-day intervals or earlier. To determine the robustness of our computations, as a secondary analysis we recomputed durations of CCB and ACEi use not including overlapping dispensings as stockpiled medications. Using the same example woman as above, if she had 20 dispensings containing 60 days' supply each and consistently obtained refills 50 days after the previous dispensing, her cumulative days' supply was 1,000 in the secondary analysis.
We did not include a variable for length of study followup in the primary or secondary adjusted analyses, because duration of CCB or ACEi use and length of study follow-up were measured on the same time scale and were highly correlated (r = 0.76). However, because women with very long follow-up times had a greater opportunity to have breast cancer detected than women with shorter follow-up, to adjust for any differential length of study follow-up between CCB and ACEi users we identified a subcohort of women with frequency-matched lengths of follow-up. After preparing the matched subcohort, we completed analyses using the same techniques as in the primary analysis.
Because we required women to have ≥2 hypertension diagnoses but both diagnoses did not have to occur prior to CCB or ACEi initiation, there was potential for selection bias. To assess this, we conducted an analysis restricted to women with ≥2 hypertension diagnoses prior to initiation of CCB or ACEi use. All statistical analyses were conducted using SAS, version 9.2 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
The cohort included 19,674 (17.9%) women taking CCBs and 90,078 (82.1%) women taking ACEis for mean durations of 3.8 (standard deviation, 2.7) years and 4.1 (standard deviation, 2.8) years, respectively. Women taking CCBs were older (CCBs, mean age = 68.6 years; ACEis, mean age = 67.2 years), had a lower mean body mass index (CCBs, 29.1; ACEis, 29.9), included a lower proportion of Hispanics (CCBs, 12.7%; ACEis, 18.9%), more frequently used angiotensin-receptor blockers (CCBs, 17.0%; ACEis, 10.9%), less frequently used thiazide-type diuretics (CCBs, 53.6%; ACEis, 68.3%) or metformin (CCBs, 4.1%; ACEis, 10.6%), and had a lower prevalence of diabetes (CCBs, 20.9%; ACEis, 35.8%) ( Table 1 ). More women were censored from the CCB cohort due to switching to an ACEi (36.3%) than from the ACEi cohort due to switching to a CCB (25.6%). Two percent (n = 397) of CCB users and 1.9% (n = 1,733) of ACEi users were diagnosed with incident invasive breast cancer.
Hazard ratios and 95% confidence intervals for durations of CCB use of up to 12 years are shown in Table 2 . Compared with using CCBs for 1-<2 years, in adjusted analysis there was no association between increasing durations of CCB use and breast cancer risk. The results of the analysis restricted to women with ≥2 hypertension diagnoses prior to the first CCB dispensing (n = 10,791) were similar (see Web  Table 1 , available at http://aje.oxfordjournals.org/).
Hazard ratios and 95% confidence intervals for ACEi use durations of up to 12 years are also shown in Table 2 Table 2 ).
The results of the secondary analysis of CCB use, in which overlapping dispensings and stockpiled medications were not included in duration of use, did not differ from the results of the primary analysis. Compared with using CCBs for 1-<2 years, the adjusted hazard ratio for all durations of use up to 12 years revealed no increased breast cancer risk. Compared with using ACEis for 1-<2 years, the adjusted hazard ratios for all durations of ACEi use up to 12 years had point estimates consistent with decreased breast cancer risk.
The subcohort matched on length of follow-up included 17,320 (17.9%) women taking CCBs and 79,304 (82.1%) women taking ACEis. In this subset of women, 358 (2.1%) CCB users and 1,594 (2.0%) ACEi users developed breast cancer. In this subcohort, longer durations of CCB use were not associated with increased breast cancer risk (Table 3) . Breast cancer risk among ACEi users again decreased with longer durations of use.
In primary analysis, the hazard profile of CCB users did not show an increasing or decreasing trend (P = 0.06). The hazard profile of ACEi users suggested a decreasing duration association over time (P < 0.001) (Figure 2A) . The P value from the test of difference in trend of the duration association between CCBs and ACEis was not significant (P = 0.81). In the matched subcohort, the P value from the trend test of the duration association between CCB use and ACEi use was significant (P = 0.02) ( Figure 2B ). In the analysis restricted to women with ≥2 hypertension diagnoses prior to cohort entry, the hazard profiles of CCB users (P = 0.55) and ACEi users (P < 0.001) were similar to those of the primary analyses. The P value from the trend test of the duration association between CCB use and ACEi use was significant (P = 0.02) ( Figure 2C ), similar to the situation with the matched subcohort.
DISCUSSION
In this large cohort of older US women with hypertension, in comparison with taking a CCB for 1-<2 years, taking a CCB for 2-<12 years was not associated with increased risk of invasive breast cancer. Taking an ACEi for 2-<12 years conferred a protective association against breast cancer as compared with taking an ACEi for 1-<2 years.
These findings were consistent regardless of whether or not the cumulative exposure to CCBs or ACEis included stockpiled medication. When risks of breast cancer were compared between women taking CCBs and those taking ACEis in a subcohort matched on length of follow-up, the duration association of ACEi use differed from the duration association of CCB use. It appears that the similarity of follow-up times strengthened the protective association of ACEi use.
The protective association with ACEi use was observed within 2-<3 years of initiation (Table 2) . Point estimates declined, plateaued, and declined again across years 3-<12. After year 7-<8, the 95% confidence intervals were wider. We could not determine whether there was a further risk reduction after year 8.
Our finding that CCB use does not increase breast cancer risk is consistent with most cohort (1, 4, 6, 31, 32) , casecontrol (7, 8, 33, 34) , and nested case-control (35) studies. Our results differ from those of 2 other US studies, a cohort study by Saltzman et al. (11) and a case-control study by Li et al. (9) . They also differ from those of a case-control study conducted by Leung et al. (36) in Taiwan. Saltzman et al. found that, compared with women with no use of antihypertensive medication, women with recent CCB use had a 1.6-fold increased risk of breast cancer (95% CI: 1.0, 2.5) (11) . Differences in study design and analysis between their study and ours that could contribute to different findings include the fact that they did not have a new-user cohort and probably had incomplete CCB data because use was determined from prescription label review. Further, they collected comorbidity data from self-administered questionnaires (potential recall bias). Finally, they did not consider concomitant use of antihypertensive agents or mammography.
In the Li et al. study, CCB use for ≥10 years was associated with a 2.4-fold higher risk of ductal breast cancer (95% CI: 1.2, 4.9) and a 2.6-fold higher risk of lobular breast cancer (95% CI: 1.3, 5.3) (9). Li et al. reduced recall bias by focusing on current CCB use and had interviewers record use from i Within the year prior to cohort entry and through the end of the woman's unique study time period. j Calculated as the total sum of days' supply of dispensed prescription medications. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio. a Discrete-time survival analysis for the association between cumulative duration of CCB or ACEi use and breast cancer risk. Crude breast cancer hazards for yearly periods were obtained using the life-table approach. A complementary log-log binary model was used to estimate duration associations.
b Adjusted for time-varying and fixed covariates. Time-varying covariates included age, body mass index (weight (kg)/height (m) 2 ), hysterectomy, diabetes, alcohol abuse, estrogen replacement, use of statins, mammography, and use of angiotensin receptor blockers, β-blockers, and/ or diuretics. Fixed covariates included Kaiser Permanente site (Colorado, Northwest, or Southern California), race/ethnicity, education, and year of cohort entry.
participants' prescription bottles. However, some exposure misclassification probably remained. They did not consider concomitant use of antihypertensive agents.
Leung et al. found a 16% increase in breast cancer risk (95% CI: 1.06, 1.28) among women in the highest quartile of cumulative CCB dose and increasing risk with increasing duration of exposure (test for trend: P = 0.006) (36) . Leung determined CCB dispensings from the Taiwan National Health Insurance Research Database. That database does not include information on body mass index, a breast cancer risk factor. They did not consider concomitant use of antihypertensive agents.
Most published studies of ACEi use and breast cancer have found either no increased risk or a nonsignificant risk reduction (1, 4, 7-10, 36, 37), including the Li et al. study discussed above (9). Li et al. found ACEi use for ≥10 years to be associated with an odds ratio of 0.7 (95% CI: 0.5, 1.2) for invasive ductal carcinoma and an odds ratio of 0.6 (95% CI: 0.4, 1.0) for invasive lobular carcinoma (9). As we mentioned above, their study had potential exposure misclassification and did not account for use of multiple antihypertensive agents. In addition, the size of our study population exceeded that in the Li et al. study, potentially contributing to our significant finding.
Our findings reflect differences in ACEi and CCB prescribing patterns. For example, ACEis may be preferred in women with diabetes for their kidney-protective effects (35.8% of the ACEi group had diabetes vs. 20.9% of the CCB group). Dual antihypertensive therapy with a thiazide-type diuretic is common (thiazide-type diuretics were used by 68.3% of the ACEi group and 53.6% of the CCB group). Use of CCBs as first-line antihypertensive agents has declined recently and may account for the low proportion of women (17.9%) initiating use of a CCB and the high proportion (36.3%) switching to an ACEi.
Our findings that long-term use of CCBs was not associated with increased risk of breast cancer and that long-term use of ACEis may be associated with reduced risk of breast cancer have public health and treatment implications. The prevalence of hypertension among women aged ≥55 years ranges from 52% (at age 55-64 years) to 80% (at age ≥75 years) (38) , and most hypertensive women are prescribed medication. Our findings reassure prescribers and women with hypertension about the association between long-term use of CCBs or ACEis and breast cancer.
The proposed mechanism by which CCBs increase breast cancer risk was based on cell-line studies demonstrating that blockade of calcium channels inhibited apoptosis, enabling division of damaged cells with malignant potential (39) . Subsequent evaluation did not support this hypothesis (40) .
The proposed mechanism by which ACEis reduce breast cancer risk over time is related to angiotensin II. Angiotensin II stimulates neovascularization and acts as a growth factor (10) . ACEi inhibits angiogenesis and the growth of induced cancer in rats (10) . Given that angiotensin II production decreases soon after ACEi initiation, our findings that the protective association was observed relatively early and that there might not be additional risk reduction after years of therapy is plausible. Further research would be needed to clarify this.
In addition to the fact that our cohort included thousands of women with years of CCB or ACEi use, another strength of our study is that we determined CCB or ACEi use from prescription dispensings, a more accurate method than self-reporting (1, 8, 9, 11, 33, 34) . Other strengths are that we included women with diagnosed hypertension (reducing potential confounding by indication) and identified confounders and cancers using longitudinal databases. Finally, to ensure that immortal time bias was not a concern, we used an exposure-defined cohort, setting the index date to the date of the first dispensation of a CCB or ACEi. Even if the date of a woman's qualifying prescription fell between her first and second hypertension diagnoses, the person-time between diagnoses was not event-free. The definition of ACEi or CCB initiation was the same for all women, and breast cancer could occur at any time after initiating use of the ACEi or CCB (41) (42) (43) .
Our study also had limitations. Residual confounding is a concern in any observational research. To reduce the potential for residual confounding, we adjusted for known confounders. However, some possible confounders, such as age at menopause, could not be controlled for because information on them was not available in the electronic data. We believe misclassification of menopausal status was very low, because ≥95% of women reach menopause by age 55 years (15, 44) . Our definition of "new user" required no CCB or ACEi use in the prior year, and a few women could have had more remote exposure. However, missed use prior to cohort entry would have resulted in underclassification of total duration. It is also feasible that a few women could have used β-blockers, angiotensin receptor blockers, or diuretics prior to the look-back period only. Similar to previous studies of cancer risk and medication use, we did not consider the competing risk of death with longer duration of use, nor did we consider the duration of hypertension prior to ACEi or CCB initiation. Finally, including only women with diagnosed hypertension reduced the generalizability of our findings.
We conclude that CCB use for up to 12 years does not increase the risk of developing invasive breast cancer in older women with hypertension. We further conclude that treatment with ACEis for up to 12 years may confer protection against the development of invasive breast cancer. These findings can assist prescribers when they are counseling older women with hypertension on the long-term use of CCBs or ACEis. Hazard rates for risk of breast cancer according to longterm use of a calcium channel blocker (CCB) or angiotensinconverting enzyme inhibitor (ACEi) among women in a cohort selected from 3 Kaiser Permanente sites, 1997-2012. A) All women (n = 109,752; CCB test for trend: P = 0.06; ACEi test for trend: P < 0.001; test for difference in linear trend of duration association between CCBs and ACEis: P = 0.81); B) women in the subcohort matched on length of follow-up time (n = 96,624; CCB trend test: P = 0.41; ACEi trend test: P < 0.001; test for difference in linear trend of duration association: P = 0.02); C) women with at least 2 diagnoses of hypertension prior to CCB or ACEi prescription (n = 57,721; CCB trend test: P = 0.55; ACEi trend test: P < 0.001; test for difference in linear trend of duration association: P = 0.02 (limited to >1-9 years' duration of use because there were no breast cancer outcomes in this CCB subgroup after year 9)). Bars, 95% confidence intervals. This study was funded through internal operational funds provided by the Kaiser Permanente Center for Effectiveness and Safety Research (CESR). The CESR facilitates interregional research conducted in each of the 7 regional entities (Colorado, Georgia, Hawaii, Mid-Atlantic States (Virginia, Maryland, District of Columbia), Northern California, Northwest (Oregon, Washington), and Southern California) that comprise the Kaiser Permanente integrated health-care organization.
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